Researchers identify key source of T cell ‘exhaustion’

Discovery from researchers at Dana Farber Cancer Center and collaborators opens the way to drugs that can prevent T-cell therapies from losing their potency over time. Read more about the encouraging findings for future HIV/AIDS and Cancer therapy from The Dana below.

The co-first authors of the study are Elena Battistello, PhD, of the Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, and Kimberlee Hixon, and Dawn E. Comstock, of Dana-Farber and the Broad Institute.  The co-authors are W. Nicholas Haining, BM, BCh, and Jun Qi, PhD, of Dana-Farber; Clayton K. Collings, PhD, Kasey S. Cervantes, and Madeline M. Hinkley, of Dana-Farber and the Broad Institute; Xufeng Chen, PhD, Javier Rodriguez Hernaez, MSc, Soobeom Lee, MSc, Konstantinos Ntatsoulis, MSc, and Aristotelis Tsirigos, PhD, of the Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine; Kathryn Hockemeyer, MD, PhD, of NYU and Dana-Farber; Annamaria Cesarano, MSc, and Fabiana Perna, MD, PhD, of Indiana University School of Medicine; and Matthew T. Witkowski, PhD, of the University of Colorado.
This work was supported in part by the National Institutes of Health (grants  1F31CA271427-0, 5F30CA239317, T32GM007753, T32GM144273, and 1DP2CA195762), the Switzerland National Science Foundation; the Lymphoma Research Foundation; the National Cancer Institute (grants 5R01CA173636, 5R01CA228135, 5P01CA229086, 5R01CA242020, 1R01CA243001, and 1R01CA252239); the Mark Foundation for Cancer Research Emerging Leader Award, the Vogelstein Foundation. NYU Langone’s Genome Technology Center is partially supported by the Cancer Center Support grant P30CA016087 at the Laura and Isaac Perlmutter Cancer Center.